Participant flow

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma · Source last updated 2025-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.

   id

   FG000

   title

   DKN-01 Monotherapy in Recurrent EEC

2. description

   300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 administered by IV infusion.

   id

   FG001

   title

   DKN-01+Paclitaxel in Recurrent EEC

3. description

   300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.

   id

   FG002

   title

   DKN-01 Monotherapy in Recurrent EOC

4. description

   300mg DKN-01+paclitaxel in recurrent EOC. DKN-01and paclitaxel administered by IV infusion.

   id

   FG003

   title

   DKN-01+Paclitaxel in Recurrent EOC

5. description

   300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

   id

   FG004

   title

   DKN-01 300mg Monotherapy in Carcinosarcoma

6. description

   600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

   id

   FG005

   title

   DKN-01 600mg Monotherapy in Carcinosarcoma

7. description

   300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

   id

   FG006

   title

   DKN-01 300mg + Paclitaxel in Carcinosarcoma

8. description

   600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

   id

   FG007

   title

   DKN-01 600 mg + Paclitaxel in Carcinosarcoma

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         29

      2. group Id

         FG001

         num Subjects

         24

      3. group Id

         FG002

         num Subjects

         14

      4. group Id

         FG003

         num Subjects

         19

      5. group Id

         FG004

         num Subjects

         1

      6. group Id

         FG005

         num Subjects

         8

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         12

      comment

      Number Started is the Safety Analysis Set defined as all subjects who received \>= 1 administration of assigned study treatment (DKN-01 or paclitaxel).Subjects with carcinosarcoma were initially enrolled in the EEC group to receive monotherapy or DKN-01+paclitaxel, but as part of a subsequent protocol amendment, carcinosarcoma subjects were enrolled \& received 600mg DKN-01 or 600mg DKN-01+paclitaxel. Results are reported by disease type and treatment received.

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         26

      2. group Id

         FG001

         num Subjects

         21

      3. group Id

         FG002

         num Subjects

         13

      4. group Id

         FG003

         num Subjects

         19

      5. group Id

         FG004

         num Subjects

         1

      6. group Id

         FG005

         num Subjects

         8

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         10

      comment

      Number Completed is the Evaluable Analysis Set defined as all subjects who received any amount of DKN-01 and had at least 1 evaluated post-baseline RECIST assessment or were discontinued due to death.

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice